Clinical Trial Update: Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a biomarker-based cockroach sublingual immunotherapy (BioCSI) for allergic rhinitis and asthma completed, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma

Drugs mentioned

• BioCSI Cockroach Sublingual Immunotherapy

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Rhinitis, Allergic, Perennial, Asthma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-03-08